SpyGlass Pharma, Inc. Common Stock
NASDAQ:SGPBiotechnology
+$0.45 today
- Market cap
- $993.14M
- Beta
- -0.34
- P/E (TTM)
- -14.1
- EPS (TTM)
- -$1.32
Volume 0.10M
Average 0.09M
SGP Capital Expenditures
Cash spent on property, plant, equipment, and other long-term assets.
SpyGlass Pharma, Inc. Common StockNASDAQ: SGP
Capital Expenditures · Q1 FY2026 · quarter ended Mar 2026
Capital expenditures of -$676K in Q1 FY2026
Q1 FY2026 capital expenditures was -$676K.
Sources:Cash FlowText generated from reported figures; not investment advice.
Capital Expenditures history
USD · from the cash flow
- Latest · FY2025
- (789K) USD
- Year-over-year change
- —
| Period | Period end | Capital Expenditures | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (789K) | — |
Capital Expenditures vs competitors
How SGP compares with its peers on the latest reported figures
- Peers report in different currencies, so capital expenditures is compared through growth and share of revenue rather than absolute size.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $582.3M USD | -0.1% | -3.8% | 5.3% | |
| LTM Jun 2026 | $318.06M USD | -9.4% | +25.9% | 6.0% | |
| LTM Mar 2026 | $14.74M USD | +396.9% | +47.9% | 28.3% | |
| LTM Jun 2026 | $11.25M USD | +78.5% | -36.7% | 1.8% | |
| LTM Apr 2026 | $4.8M USD | +140.8% | -31.5% | 1.7% | |
| LTM Mar 2026 | $4.01M USD | -0.8% | +17.0% | 3.1% | |
| LTM Mar 2026 | $4M USD | +27.7% | +15.1% | 52.5% | |
SGPSpyGlass Pharma, Inc. Common Stock | FY2025 | $789K USD | — | — | — |
| LTM Mar 2026 | CHF 294.17K CHF | -77.9% | -56.7% | 58.4% | |
| LTM Mar 2026 | $284K USD | +6.0% | -38.6% | 0.4% | |
| Peer median (excluding SGP) | — | +6.0% | -3.8% | 5.3% | |
Competitors are the stored peer set for SGP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2025 Dec 2025 |
|---|---|
| Net Income | (39.87M) |
| Depreciation & Amortization | 612K |
| Deferred Income Tax | 0 |
| Stock-Based Compensation | 2.79M |
| Change in Working Capital | 2.45M |
| Accounts Receivables | (8K) |
| Inventory | 0 |
| Accounts Payables | 549K |
| Other Working Capital | 1.91M |
| Other Non-Cash Items | 1.32M |
| Operating Cash Flow | (32.7M) |
| Capital Expenditures | (789K) |
| Acquisitions (Net) | 0 |
| Purchases of Investments | (17M) |
| Sales of Investments | 6M |
| Other Investing Activities | 0 |
| Investing Cash Flow | (11.79M) |
| Debt Repayment | 0 |
| Common Stock Issued | 170K |
| Common Stock Repurchased | (1.45M) |
| Dividends Paid | 0 |
| Other Financing Activities | (1.47M) |
| Financing Cash Flow | 124.59M |
| Effect of Forex Changes | 0 |
| Net Change in Cash | 80.09M |
| Free Cash Flow | (33.49M) |
SpyGlass Pharma, Inc. Common Stock
NASDAQ:SGP
Intrinsic Alpha fair value
Locked
Current Price
$29.68
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.